Background Degradation of extracellular matrix by tumorassociated proteases can promote cell invasion and metastasis This study assessed the prognostic role of MMP2, MMP9 metalloproteinases, and of the metalloproteinase inhibitor T1MP2, related to disease-free survival (DFS), in soft tissue sarcoma (STS) patients Materials and methods Level and distribution of MMP2, MMP9, and TIMP2 expression were evaluated on 73 biopsies by immunohistochemistry and lmmunoblotting Biopsies included 29 hposarcomas, 29 synovial sarcomas, and 15 malignant peripheral nerve sheath tumors (MPNST) Association between DFS and overall survival with different variables was assessed.
Introduction
Tumor metastasis is a multi-step process involving biochemical events that lead to invasion by malignant cells of basement membrane and connective tissue [1] . The earliest stage of invasion is an increased permeability of extracellular matrix (ECM) to cell movement due either to a decresed synthesis of its components or to a ECM degradation by tumor cell-associated proteases [2] Metastatic cells secrete a large amount of metalloproteases (MMPs) which can degrade ECM components [3] . An increased expression of MMPs in tumor cells was found correlated with their metastatic potential [4, 5] . Among the MMP family, MMP2 (gelatinase A, 72-kDa) and MMP9 (gelatinase B, 92-kDa) were correlated to aggressiveness in human cancer [6] [7] [8] . In contrast, the presence of specific MMP inhibitors (TIMPs) can suppress metastasis preserving ECM integrity in vitro [9] and in experimental animals [10] . However, some studies [7] reported a positive relationship between TIMP2 expression, a specific inhibitor of 72-kDa gelatinase, and poor outcome in invasive tumors Nevertheless, an unbalance in the expression of these enzymes seems to strongly contribute towards tumor invasion [11] .
Soft tissue sarcomas (STS) are a heterogeneous group of tumors with features so similar that differential diag-nosis is often uncertain. STS represent < 1% of cancers in adults and from 7% to 10% of childhood cancers. Fifteen percent to twenty percent of these tumors are poorly differentiated Liposarcoma is the second most frequent malignant STS, and its cells differentiate in lipoblasts and lipocyles. It commonly occurs in the adult and elderly, and is localized in the thigh, retroperitoneum, inguinal region, and popliteal fossa.
Synovial sarcomas represent 5%-10% of all STS and may differentiate into two morphologically distinct types of cells (epithelial and mesenchymal) It mainly affects young adults between 15 and 40 years of age and, in the majority of cases, arises in the lower limbs Schwannoma, or malignant peripheral nerve sheath tumor (MPNST), is a rare spindle cell tumor (< 10% of all STS) of the adult, with Schwann cell differentiation, but also with variations in histological patterns. It arises in the extremities in association with large nerves. Immunohistochemical markers for neurogenic differentiation are of help in differential diagnosis with fibrosarcoma and monophasic synovial sarcoma [12] .
Surgery is usually the treatment of choice for patients with high-grade STS, but less than 50% have a five-year survival. Adjuvant therapies, such as pre-and postoperative chemoterapy, have given controversial results.
The investigation of factors that influence growth and spread of tumor cells is needed to develop new and more specific therapies. Expression and distribution of MMP2, MMP9, and TIMP2 proteins were evaluated in relation to occurrence of metastasis and clinical outcome in patients with STS
Materials and methods
The study was carried out on 73 biopsies of primary STS from patients (40 males, 33 females), who underwent surgery at the Rizzoh Institute Only untreated cases with adeguate histological material and complete clinical data were included The patient age ranged from 4-92 years, with a median of 42 years Only 7 patients were less than 18 years old Tumor biopsies included 29 liposarcomas 11 low-grade (4 well differentiated and 7 myxoid) and 18 high-grade (4 round cell and 14 pleomorphic), 29 high-grade synovial sarcomas (SS) 14 spindle cell monophasic and 15 biphasic, and 15 MPNST 4 low grade 1-2 and II high grade 3-4 For each sample both frozen and paraffin-embedded material was available We used samples that were frozen immediatly after biopsy, which was a limit to the selection of the cases included in this study All tumors were diagnosed at the Rizzoh Orthopaedic Institute by a team of pathologists particulary expert in the diagnosis of sarcomas Diagnoses were based on hematoxylin-eosin stained samples For differential diagnosis immunohistochemical analysis with specific antibodies was used Grading was coded according to Broders' criteria [13] Immunohistochemistry (IHC) IHC was performed on deparaffinized sections using the streptoavidinbiotin complex (sABC) method (AutoProbe III, Biomeda, Foster City, California) After treatment with Endo Blocker reagent (Biomeda, dilution I 5) to eliminate endogeneous peroxidase, blocking serum (Biomeda) and pepsin solution (Lab-Vision, Fremont, California), the sections were incubated at +4 °C overnight with primary antibodies MMP2 (Neomarkers, Union City, California, USA, dilution 1 50), MMP9 (Oncogene, Cambridge, Maryland, USA, dilution 1 5) and T1MP2 (Neomarkers, Union City. California, USA. dilution 1 5) Then, secondary biotinylated antibody and sABC complex were applied, the slides were developed in 3-annno-9-ethylcarbazole, and counterstained with hematoxylin Cell positivity percentage was classified as 0%-l0% (negative), ll%-25% (weak), 26%-49% (moderate), 50%-100% (strong) A 10% cut-off was used for TIMP2 staining, while for increased expression of MMP2 and MMP9 the cut-off used was 25% positive cells
Immunoprecipitation and immunoblotting (IB)
According to standard procedure [14] , protein extracts were prepared by mincing and homogenizing fresh samples in extraction buffer (50mM Tns-HCI pH 8. 150 mM NaCI, 1 mM DTT, 50 mM NaF, 0 5% sodium deoxycholate, 0 1% SDS, 1% NP-40, 0 1 mM PMSF, 2 ug/ml aprotinin, 1 ug/ml leupeptin, 100 mM Na3VO4) Samples of 200 ug of each protein extract were immunoprecipitated with the antibodies to MMP2, MMP9 and TIMP2. The precipitates were analyzed by 10% SDS-polyacrylamide gel for MMP2 and MMP9 protein, 15% SDSpolyacrylamide gel forTIMP2, at 50V for 4 hours, followed by western blotting The signal was visualized by ECL (Amersham, Aylesbury, UK) detection system and quantified by using GS-670 imaging densitometer (BIO-RAD) The adjusted volume was calculated for each band A 50 OD cut-off, corresponding to the average volume of non tumor samples, was chosen to select tumors with increased levels of MMP2andMMP9
Only cases positive to both IHC and IB were considered 
Patients and statistical analysis
Evaluation of clinical follow-up consisted of data on metastasis, time to metastasis, DFS interval, and overall survival DFS was calculated from the date of diagnosis to the last day of follow-up or event. Fortyone out of seventy-three patients were disease-free, while thirty-two developed metastasis and twelve died of disease Follow-up ranged from 3-108 months, with a mean duration of 41 months Local recurrence and metastasis at the entry were not included The clinical features of patients are reported in Table I Twenty-five patients had chemotherapy, six were given both pre-and post-operative treatment Forty-five patients had radiation therapy and of these, thirteen also had chemotherapy Sixteen patients were given no treatment
The 
Results
Of the 73 tumors studied, 48 (66%) showed a moderate to strong positive immunostaining for MMP2, 36 (49%) for MMP9, and 29 (40%) for both. The tissue inhibitor of metalloproteinases TIMP2 was positive in 49 (67%) cases ( Table 2 ). The positive cases were confirmed by IB analysis which revealed the presence of 92-kDa (>5 OD) and 21-kDa electrophoretic bands corresponding to MMP9 and TIMP2, respectively. Concerning MMP2, immunoreactivity was resolved in two bands of 62-kDa and 72-kDa corresponding to the active and latent form, respectively (> 5 OD).
Thirty-two patients had metastasis and forty-one were disease free. Twenty-eight of thirty-two (87%) and eighteen of thirty-two (56%) patients who relapsed with metastasis had tumors with increased expression of active MMP2 and MMP9, respectively. Sixteen of thirtytwo (50%) were positive for both antibodies On the other hand TIMP2 expression was positive in thirty-three of forty-one (80%) tumors from the disease-free patients ( Table 2) .
Concerning clinical parameters ( Table 1) , 23 of 32 (72%) metastatic patients had a tumor size > 10 cm. In the liposarcoma and MPNST subgroup, among the 19 patients who developed metastasis, 16 had high-grade and 3 low-grade tumors ( Table 1) .
Statistical analysis
By univanate analysis, a significant inverse association between increased MMP2 reactivity and DFS was found (chi-square = 11.9; P -0.0005), while TIMP2 positivity was directly associated to absence of metastasis (chisquare = 7.5; P -0.006). MMP2 expression was also associated to histologic grade (chi-square = 8.8; P = 0.005). No significant correlations were found for MMP9 expression.
The estimated DFS was 42% for those patients with increased MMP2 expression (20 of 48) and 84% for the those with <25%ofMMP2-positivecells(21 of 25). The difference between the two DFS curves was statistically significant (log-rank = 8.8, P -0.003) ( Figure 1) .
Inversely, DFS rate was 67% for patients with TIMP2-positive (33 of 49) and 33% for the TIMP2negative tumors (8 of 24). The difference between the two Figure 3 Disease-free survival curves for grade in 73 patients with soft tissue sarcoma DFS curves was statistically significant (log-rank = 5.0; P = 0.02) ( Figure 2 ). Using a cut-off of 10 cm, tumor size had a prognostic significance (chi-square = 4.79, P = 0.03). DFS rate was 45% for patients with tumors over 10 cm (19 of 42), and 71% when smaller (22 of 31). Tumor size was measured by computed tomography on the length of the major diameter.
For the 73 patients with STS, also the histologic grade was correlated to prognosis (chi-square = 4 35; P = 0.04). DFS rate was 50% in high grade (29 of 58) versus 80% in low grade (12 of 15), and the difference between the two DFS curves was statistically significant (log-rank = 4.34; P -0.03) ( Figure 3 ). No association with prognosis was anli-TIMP2 observed between sex, age, chemotherapy or radiation therapy and DFS. Furthermore, no association was found between all variables studied and overall survival The latter data were confirmed for the single tumor entities.
Multivariate analysis showed that high MMP2 expression was significant for poor prognosis with a relative risk for decreased DFS of 3.18 (Table 3) .
Synovial sarcoma
Based on cellular differentiation, SS were subdivided into two histologic types' spindle cell monophasic, and biphasic, in which the spindle and epithelial components were equally represented. No significant differences in clinical behaviour and prognosis were found between tumor size and histologic types Thirteen patients had metastasis, seven in the monophasic group and six in the biphasic; of these, six died of disease.
Of the 29 SS, respectively 18 (62%) and 12 (41%) had high level of MMP2 and MMP9 (Table 2, Figure 4) , with a moderate to strong staining intensity. Densitometnc and lmmunohistochemical analysis revealed no marked differences in relation to histology or clinical behaviour A significant cell accumulation of tissue inhibitor TIMP2 was seen in 15 SS (Table 2, Figure 5 ), and the expression pattern varied from moderate to strong. By univariate analysis, a significant positive association was found between TIMP2 expression and DFS (chi-square = 7 74; P = 0.009). DFS estimate was 80% in patients with TIMP2-positive tumors (12 of 15), and 28% in those with TIMP2-negative tumors (4 of 14) . The logrank test used to compared the DFS curves based on TIMP2 immunoreactivity was statistically significant (log-rank = 4.8; P = 0 02).
MPNST
Eight of the fifteen MPNST patients relapsed with metastasis within two years from diagnosis. Seven of eight had high-grade tumors ( Table 1 ) and two of these died. DFS estimate was 75% in the low-grade (3 of 4) and 36% in the high-grade group (4 of 11), but the difference was not statistically significant All tumors that developed metastasis were > 10cm and tumor size had a poor prognostic significance (chi-square = 8.57, P = 0.007). Thirteen of fifteen (87%) and four of fifteen (27%) tumors immunostained for MMP2 and MMP9 respectively ( Table 2) from moderate to strong (Figures 6 and 7) and no significant association was found between protease immunoreactivity and metastasis, or grade Blotting analysis confirmed the high amount of 62-kDa MMP2 in almost all samples, whereas MMP9 was weak or absent.
TIMP2 lmmunostaining was moderate in eight tumor samples (Table 2) , with no significant association with malignancy degree or clinical outcome. In these eight tumor samples, the reactivity was resolved in a thin detectable 21-kDa band.
Liposarcoma
Twenty-nine patients with liposarcoma were studied. Eleven of twenty-nine had metastasis within three years from diagnosis and nine of the latter had a high-grade tumor ( Table 1) ; of these three died DFS estimate was 82% in the low-grade group (9 of 11) and 50% in the high-grade (9 of 18), but the difference between the two probability curves was not statistically significant In terms of DFS, tumor size proved to be a significant prognostic factor since only one patient with tumor smaller than 10 cm had metastasis (Table 1 ) (chi-square = 4.71 ;P-004).
For protease immunoreactivity ( Table 2) , 17 of 29 (59%) tumors had increased MMP2 immunostaining and high levels of 62-kDa protein (Figure 8 ) Strong MMP9 immunostaining was seen in more than 50% of tumor cells in 20 of 29 hposarcomas (69%) (Figure 9 ). In these, IB showed a large 92-kDa band revealing the presence of high levels of this protease.
In terms of DFS the increased expression of MMP2 and MMP9 expression was significant for poor prognosis (chi-square = 7.6, P = 0.008 and chi-square = 7.97, P -0.005, respectively). DFS estimate was 41% in the group with > 25% of MMP2 positive cells (7 of 17) and 92% in that with weak or undetectable MMP2 reactivity (11 of 12). The difference between the DFS curves was statistically significant (log-rank = 6.0; P = 0.01).
All 11 metastatic patients, 2 low grade and 9 high grade, had a moderate to strong MMP9 expression, while MMP9 increased positivity was seen in 9 of 18 (50%) of the disease-free patients ( Table 2) . By univariate analysis, a strong association between MMP2 and MMP9 expression and histologic grade was also found (chi-square = 11.94; P = 0.0013 and chi-square = 4.58, P -0.04, respectively).
Twenty-six out of twenty-nine liposarcomas (90%) had > 10% of tumor cell nuclei positive toTIMP2 antibody ( Table 2 ). The three tumors lacking TIM P2 expression were found in the high-grade group and developed metastasis.
Conclusions
Soft tissue sarcomas have generally been studied less extensively than bone tumors, so their anatomo-clinical features, biological behaviour, development and prognosis have to be better defined. Traditional cytological criteria for malignancy are of relative value for each tumoral entity [16] . Besides the proliferation index Ki67, prognostic markers for STS have not been well identified. Our previous studies established a prognostic role of laminin receptor expression, in terms of diseasefree survival, in a series of soft tissue sarcomas [17] . Metalloproteinase expression was found significantly strong in tumors compared to normal tissues [18] . Other studies associated, in vivo and in vitro, a metalloproteinase increased secretion with metastatic phenotype of tumor cells [5] . Recently, the invasiveness of human epithehoid sarcoma, a very aggressive soft tissue neoplasm, has been associated with cell motility, and inversely correlated withTIMPs expression [19] . IHC studies on human tumors, confirmed that loss of basement membrane integrity, primarily involved in the invasive process, was associated with an increased expression of type IV collagenases, MMP2 and MMP9 [20] . In the present study, 32 patients developed metastasis, with increased expression of MMP2 and MMP9, respectively, in 87% and 56% of the cases. In contrast, TIMP2 expression was seen in 80% of the 41 disease-free patients. By univanate analysis, active MMP2 and lack of TIMP2 expression had an important significance for poor prognosis. Multivariate analysis demonstrated the significance of MMP2 62-kDa protein overexpression as risk factor in a decreased disease-free survival.
Tumor size larger than 10 cm and high grade were also associated with a less favorable DFS.
To define a relationship between prognostic markers and cell differentiation, the 73 tumors were subdivided in three groups on the basis of histogenesis and histology. In the 29 cases of liposarcoma, increased expression of both MMP2 and MMP9 showed a positive significant association with metastatic event and tumor grade, in accordance with other studies that found that gelatinases expression correlated with tumor grade and patient outcome, and underlined the prevalent role of MMP9 in predicting the metastatic event [8, 21, 22] . On the contrary, the consistent presence of TJMP2 protein in 90% of liposarcomas neither had statistical significance in terms of DFS nor correlated with histologic grade. TIMP2 analysis revealed its significant role as marker of good prognosis in synovial sarcomas. In this group high levels of metalloprotease inhibitor were seen in disease-free patients independently of the histological component In MPSNT, in spite of the presence of active MMP2 protein in 87% of tumor samples, the expression of metalloproteinases was moderate and irregular. Our previous study [17] showed a clear downregulation of MMP2 substrate, type IV collagen, in MPSNT in comparison with non-neoplastic nerve tissue.
Although the statistical analysis for each sarcoma group was less significant compared to that of the entire series, because of the reduced number of the patients, these data suggest an unbalance of proteases/protease inhibitor system in all three sarcoma types Adjuvant therapies, such as pre-and post-operative chemoterapy have improved prognosis of osteosarcoma and Ewing's sarcoma [23, 24], but contradictory results have been reported for other sarcoma types In spite of the fact that radiotherapy is frequently used as an adjuvant to surgery in STS, a significant percentage of patients with high grade tumors develop distant metastatic disease [25] The identification of prognostic markers influencing growth and tumor spread is important to define high-risk patients and to differentiate treatment protocols accordingly
